Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 485

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma

Open access
Zhukova, Nataliya, Ramaswamy, Vijay, Remke, Marc, Pfaff, Elke, Shih, David J.H., Martin, Dianna C., Castelo-Branco, Pedro, Baskin, Berivan, Ray, Peter N., Bouffet, Eric, von Bueren, André O., Jones, David T.W., Northcott, Paul A., Kool, Marcel, Sturm, Dominik, Pugh, Trevor J., Pomeroy, Scott L., Cho, Yoon-Jae, Pietsch, Torsten, Gessi, Marco, Rutkowski, Stefan, Bognar, Laszlo, Klekner, Almos, Cho, Byung-Kyu, Kim, Seung-Ki, Wang, Kyu-Chang, Eberhart, Charles G., Fevre-Montange, Michelle, Fouladi, Maryam, French, Pim J., Kros, Max, Grajkowska, Wieslawa A., Gupta, Nalin, Weiss, William A., Hauser, Peter, Jabado, Nada, Jouvet, Anne, Jung, Shin, Kumabe, Toshihiro, Lach, Boleslaw, Leonard, Jeffrey R., Rubin, Joshua B., Liau, Linda M., Massimi, Luca, Pollack, Ian F., Shin Ra, Young, Van Meir, Erwin G., Zitterbart, Karel, Schüller, Ulrich, Hill, Rebecca M., Lindsey, Janet C., Schwalbe, Ed C., Bailey, Simon, Ellison, David W., Hawkins, Cynthia, Malkin, David, Clifford, Steven C., Korshunov, Andrey, Pfister, Stefan, Taylor, Michael D., Tabori, Uri·2013·Journal of Clinical Oncology

Abstract

Purpose: Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. Patients and Methods: We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent cohort of 156 medulloblastomas. Results: TP53 mutations are enriched in wingless (WNT; 16%) and sonic hedgehog (SHH; 21%) medulloblastomas and are virtually absent in subgroups 3 and 4 tumors (P < .001). Patients with SHH/TP53 mutant tumors are almost exclusively between ages 5 and 18 years, dramatically different from the general SHH distribution (P < .001). Children with SHH/TP53 mutant tumors harbor 56% germline TP53 mutations, which are not observed in children with WNT/TP53 mutant tumors. Five-year overall survival (OS; ± SE) was 41% ± 9% and 81% ± 5% for patients with SHH medulloblastomas with and without TP53 mutations, respectively (P < .001). Furthermore, TP53 mutations accounted for 72% of deaths in children older than 5 years with SHH medulloblastomas. In contrast, 5-year OS rates were 90% ± 9% and 97% ± 3% for patients with WNT tumors with and without TP53 mutations (P = .21). Multivariate analysis revealed that TP53 status was the most important risk factor for SHH medulloblastoma. Survival rates in the validation cohort mimicked the discovery results, revealing that poor survival of TP53 mutations is restricted to patients with SHH medulloblastomas (P = .012) and not WNT tumors. Conclusion: Subgroup-specific analysis reconciles prior conflicting publications and confirms that TP53 mutations are enriched among SHH medulloblastomas, in which they portend poor outcome and account for a large proportion of treatment failures in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.48.5052

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 485

Metadata

Authors
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., von Bueren, A. O., Jones, D. T. W., Northcott, P. A., Kool, M., Sturm, D., Pugh, T. J., Pomeroy, S. L., Cho, Y.-J., Pietsch, T., Gessi, M., Rutkowski, S., Bognar, L., Klekner, A., Cho, B.-K., Kim, S.-K., Wang, K.-C., Eberhart, C. G., Fevre-Montange, M., Fouladi, M., French, P. J., Kros, M., Grajkowska, W. A., Gupta, N., Weiss, W. A., Hauser, P., Jabado, N., Jouvet, A., Jung, S., Kumabe, T., Lach, B., Leonard, J. R., Rubin, J. B., Liau, L. M., Massimi, L., Pollack, I. F., Shin Ra, Y., Van Meir, E. G., Zitterbart, K., Schüller, U., Hill, R. M., Lindsey, J. C., Schwalbe, E. C., Bailey, S., Ellison, D. W., Hawkins, C., Malkin, D., Clifford, S. C., Korshunov, A., Pfister, S., Taylor, M. D., & Tabori, U.
Venue
Journal of Clinical Oncology
Published
2013-08-10
Volume
31
Issue
23
Pages
2927-2935
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2129331946
Cited by
485
References
35
FWCI
14.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. https://app.cochat.ai/papers/10.1200/jco.2012.48.5052
The paper
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J. H., Martin, D. C., Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., von Bueren, A. O., Jones, D. T. W., Northcott, P. A., Kool, M., Sturm, D., Pugh, T. J., Pomeroy, S. L., Cho, Y.-J., Pietsch, T., . . . Tabori, U. (2013). Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.48.5052

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.